Axsome Therapeutics Inc (AXSM) — Cash Flow-to-Debt Ratio
Latest as of June 2026:
-0.05x
Axsome Therapeutics Inc (AXSM) has a Cash Flow-to-Debt Ratio of -0.05x as of June 2026, meaning its operating cash flow of $-32.95 Million could theoretically repay 0% of its total liabilities ($678.14 Million) in one year. See financial flexibility index of Axsome Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.05x
Operating CF / Total Liabilities
Operating Cash Flow
$-32.95 Million
USD
Total Liabilities
$678.14 Million
USD
Data as of
Jun 2026
Most recent filing
Axsome Therapeutics Inc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Axsome Therapeutics Inc across 13 annual periods. For the full cash flow conversion analysis, see Axsome Therapeutics Inc cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Axsome Therapeutics Inc (2013–2025)
Year-by-year debt coverage analysis for Axsome Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.16x | $-93.41 Million | $601.51 Million | ▲ +38.1% |
| 2024 | -0.25x | $-128.41 Million | $511.48 Million | ▲ +31.3% |
| 2023 | -0.37x | $-145.08 Million | $397.26 Million | ▲ +30.4% |
| 2022 | -0.53x | $-116.51 Million | $221.92 Million | ▲ +65.0% |
| 2021 | -1.50x | $-108.23 Million | $72.15 Million | ▼ -38.3% |
| 2020 | -1.08x | $-78.46 Million | $72.34 Million | ▲ +2.2% |
| 2019 | -1.11x | $-46.38 Million | $41.83 Million | ▲ +46.7% |
| 2018 | -2.08x | $-30.05 Million | $14.44 Million | ▼ -48.1% |
| 2017 | -1.41x | $-26.47 Million | $18.84 Million | ▼ -9.9% |
| 2016 | -1.28x | $-21.28 Million | $16.64 Million | ▲ +54.8% |
| 2015 | -2.83x | $-7.44 Million | $2.63 Million | ▼ -268.3% |
| 2014 | -0.77x | $-4.60 Million | $5.99 Million | ▼ -94.1% |
| 2013 | -0.40x | $-1.63 Million | $4.13 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.